ANALISIS EFEKTIVITAS DAN BIAYA PENGGUNAAN OBAT UNTUK DISPEPSIA DI PUSKESMAS IBRAHIM ADJIE BANDUNG

• Main Author: Andini, Leanyn
• Format: Final Project
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/45126
• Institution: Institut Teknologi Bandung

Dyspepsia is group of symptoms (syndromes) such as stomachache or epigastric pain and can be followed by nausea, vomitting, bloated, early satiety, burping, regurgitation, and heartburn (Wijaya, 2013). Dyspepsia is at the top 15 th for the most diagnosed disease for out-patient care from all hospitals in West Java for all age category (1,73%) (Depkes RI, 2012). Puskesmas Ibrahim Adjie Kota Bandung recorded that dyspepsia is second most diagnosed disease for all patient with the percentage is 17,53% in 2015. Until today, there is no specific treatment for dyspepsia medication. That issue will bring an effect, that is irrational medication, so that is important to analyze the effectiveness of dyspepsia medication, based on their efficacy and cost. This research aimed to determine effectiveness medication usage build upon efficacy and cost-effective analysis. This reseach is a descriptive and observational study which has perform for adult and elderly patients who has diagnosed dyspepsia in Puskesmas Ibrahim Adjie from July 2015 until January 2016. Data that have been collected are results of NDI and SF-LDQ questionnaire, also few additional questions per patients. Based on effectiveness evaluation, combination therapy of ranitidine and antacid also omeprazole and antacid using NDI and SF-LDQ questionnaire for 101 patients, each therapy gave significant therapeutic effect statistically. Build upon NDI dan SF-LDQ questionnaire, combination therapy of ranitidine and antacid also omeprazole and antacid has no significant differences on therapeutic effect statistically (p>0,05). With using ICER analysis, combination therapy of ranitidine and antacid has ICER value by about Rp 1684,94. Combination therapy of omeprazole and antacid has ICER value by about Rp 2748,8. Based on that results, combination therapy of ranitidine and antacid is located in second quadrant, that combination therapy of ranitidine and antacid is more cost-effective than combination therapy of omeprazole and antacid. From this research we can conclude that combination therapy of ranitidine and antacid also omeprazole and antacid could provide great therapeutic effect for patient of ¸???±??ð ??± ®í ?í±? ???? ?ð??ð® ????í±?±?????ðã?ð»ð® ??¸ð»»±?±?®±?®??? ?ð?ã ­±??±±? combination therapy of ranitidine and antacid also omeprazole and antacid. Build upon ICER analysis, combination therapy of ranitidine and antacid is more cost-effective than combination therapy of omeprazole and antacid.